Erasca Pulls Forward Phase 3 Pancreatic Trial to 1H 2027 After 44% ORR Data
ERAS has more than doubled off its 52-week low of $2.75.
Summary
Erasca is moving its planned Phase 3 first-line pancreatic cancer trial into the first half of 2027, pulled forward on the strength of updated Phase 1 data for ERAS-0015. The pan-RAS molecular glue hit a 44% confirmed ORR in 25 second-line-or-later PDAC patients at 32 mg daily, including 69% in the 13 patients with KRAS G12D or G12V mutations. Responses also showed up outside pancreatic cancer: 60% confirmed ORR in second/third-line NSCLC and 75% in biliary tract cancer. Safety held up — no dose-limiting toxicities, no discontinuations among the 54 patients on 32 mg, and early combination arms with gemcitabine/nab-paclitaxel, pembrolizumab and panitumumab produced no unexpected signals. Separately, initial Phase 1 data for pan-KRAS inhibitor ERAS-4001 showed mostly low-grade adverse events and early antitumor activity, and nonclinical work supports pairing the two drugs. The stock was down 3.06% at $13.79 Friday morning despite the data, so the market is not paying up yet. Next milestones: the 2L+ NSCLC and 1L PDAC trials in 1H 2027, a 1L NSCLC Phase 3 in late 2027 to early 2028, and an ERAS-0015/ERAS-4001 combination escalation trial in 2027.
At the time of this announcement, ERAS was trading at $14.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $2.75 to $24.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.